Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 148

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 148
---
 
 future to commercialize various products for which we may obtain regulatory approval;                             |

| • |     | changes in the competitive outlook; |

| • |     | the extent to which we establish additional strategic collaborations or other arrangements; and |

| • |     | the impact of any business interruptions to our operations or to those of the third parties with whom we work. |

A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. We also expect to incur significant manufacturing costs as our CDMOs develop scaled commercial manufacturing processes. However, we do not believe that it is possible at this time to accurately project expenses through commercialization. There are numerous factors associated with the successful commercialization of LB-102or any future product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans. 98

General and Administrative Expenses General and administrative expenses consist primarily of:

| • |     | personnel expenses, including salaries, benefits and stock-based compensation, for personnel in our executive, 
 finance, corporate and business development, and administrative functions;                                     |

| • |     | professional fees for legal, patent, accounting and audit, information technology, and tax; |

| • |     | consulting services including fees paid to our board of directors; and |

| • |     | other expenses including travel expenses, rent expense, and other operating costs. |

We expect that our general and administrative expenses will increase in the future as we expand our headcount to support our continued research and development of our product candidates. We also expect to incur increased expenses associated with operating as a public company including:

| • |     | costs related to accounting, audit, legal, compliance, regulatory, 
 and tax-related services;                                          |

| • |     | costs related to compliance with the rules and regulations of the SEC and listing standards applicable to 
 companies listed on a national securities exchange;                                                       |

| • |     | director and officer insurance costs; and |

| • |     | investor and public relations costs. |

In addition, if we obtain regulatory approval for any of our product candidates and do not enter into a third-party commercialization collaboration, we expect to incur significant expenses related to building a sales and marketing team to support product sales, marketing, and distribution